Immunoglobulin Light-chain Amyloidosis: all 174 studies
Page 2 of 2. Open to participants first (58), then studies with results posted, then the rest; newest registration first within each.
- An Open-Label Study of the Safety of an Anti-CD38 Antibody Drug Conjugate (STI-6129) in Patients With AL AmyloidosisWithdrawnNCT05692908Phase 1
- Venetoclax, Daratumumab, and Dexamethasone for Systemic Light-Chain Amyloidosis With Translocation (11;14) (ALTITUDE)WithdrawnNCT05486481Phase 1/2
- Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) AmyloidosisActive, not recruitingNCT05451771Phase 1/2
- Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) AmyloidosisCompletedNCT05199337Phase 1/2
- Efficacy of [18F]Florbetaben PET for Diagnosis of Cardiac AL AmyloidosisCompletedNCT05184088Phase 3
- Detection of Amyloid Deposits in the Wrist by MRI With Mapping and High Resolution Sequences in Systemic Amyloidosis (AMYLOCARP)CompletedNCT05150353Not applicable
- Selinexor for Treatment of Light Chain Amyloidosis With Relapsed/Refractory DiseaseWithdrawnNCT04984330Early Phase 1
- A Study on the Management and Outcome of Patients With Systemic AL Amyloidosis in EuropeCompletedNCT04937777
- Daratumumab and Pomalidomide in Previously Treated Patients With AL AmyloidosisTerminatedNCT04895917Phase 2
- Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain AmyloidosisActive, not recruitingNCT04847453Phase 1
- Isatuximab as Upfront Therapy for the Treatment of High Risk AL AmyloidosisActive, not recruitingNCT04754945Phase 1
- A Study to Investigate the Relationship Between Duration of Treatment and Response in Patients With Multiple Myeloma (MM) or Systemic AL Amyloidosis Treated in Real-life PracticeCompletedNCT04659798
- A Study of Belantamab Mafodotin in Patients With Relapsed or Refractory AL AmyloidosisCompletedNCT04617925Phase 2
- Screening to Improve Survival in AL AmyloidosisCompletedNCT04615572
- Comparison of BTD and BCD Based Regimens in the Treatment of AL AmyloidosisStatus unknownNCT04612582Phase 4
- Novel Imaging Tools in Newly-diagnosed Patients With Cardiac AL AmyloidosisCompletedNCT04392960Not applicable
- Study of the Safety and Efficacy of STI-6129 in Patients With Relapsed or Refractory Systemic AL AmyloidosisStatus unknownNCT04316442Phase 1/2
- Frontline Lenalidomide for AL Amyloidosis Involving MyocardiumCompletedNCT04298372Phase 3
- Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to DaratumumabActive, not recruitingNCT04270175Phase 2
- A Clinical Study of Melphalan Flufenamide (Melflufen) and Dexamethasone for Patients With Immunoglobulin Light Chain (AL) AmyloidosisTerminatedNCT04115956Phase 1
- Screening for Systemic Amyloidosis Via the Ligamentum FlavumCompletedNCT03923920
- Cardiac Amyloidosis Screening at Trigger Finger ReleaseCompletedNCT03886155
- Ixazomib Maintenance Study in Patients With AL AmyloidosisActive, not recruitingNCT03618537Phase 2
- A Trial of Doxycycline vs. Standard Supportive Therapy in Newly-diagnosed Cardiac AL Amyloidosis Patients Undergoing Bortezomib-based TherapyTerminatedNCT03474458Phase 2/3
- Monitoring of Early Disease Progression in Hereditary Transthyretin AmyloidosisCompletedNCT03431896
- Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL AmyloidosisActive, not recruitingNCT03315026Phase 2
- Daratumumab, Ixazomib, and Dexamethasone in AL AmyloidosisCompletedNCT03283917Phase 1
- Lenalidomide, Dexamethasone, and Elotuzumab With or Without Cyclophosphamide in Treating Patients With Relapsed Primary AmyloidosisStatus unknownNCT03252600Phase 2
- Ixazomib In Combination With Cyclophosphamide And Dexamethasone for Newly Diagnosed AL AmyloidosisCompletedNCT03236792Phase 1/2
- Ibrutinib With or Without Bortezomib and Dexamethasone in Treating Patients With Relapsed or Refractory Immunoglobulin Light Chain AmyloidosisWithdrawnNCT03130348Phase 2
- Trial of Venetoclax (ABT-199) and Dexamethasone for Relapsed or Refractory Systemic AL AmyloidosisTerminatedNCT03000660Phase 1
- Daratumumab Therapy for Patients With Refractory or Relapsed AL AmyloidosisCompletedNCT02816476Phase 2
- A Diagnostic Screening Trial Seeking AL Amyloidosis Very EarlyCompletedNCT02741999
- Assessment of Minimal Residual Disease (MRD) After Antineoplastic Treatment in Patients With AL AmyloidosisCompletedNCT02716103
- Quality of Life (QOL) Registry for Patients With AL AmyloidosisCompletedNCT02574676
- Minimal Residual Disease as a Possible Predictive Factor for Relapse in Patients With AL AmyloidosisCompletedNCT02555969
- Allo SCT in Amyloidosis Non-interventional StudyCompletedNCT02257905
- Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients With AL AmyloidosisCompletedNCT02245867Phase 1
- Bortezomib and Dexamethasone Followed by ASCT Compared With ASCT Alone in Treating Patients With AL AmyloidosisCompletedNCT01998503Phase 3
- Radioimmunoimaging of Light Chain (AL) AmyloidosisCompletedNCT01815086Phase 1
- Pomalidomide With Melphalan and Dexamethasone for Untreated Systemic AL AmyloidosisTerminatedNCT01807286Phase 1
- Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood DisordersCompletedNCT01758042Not applicable
- First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDDTerminatedNCT01728259Phase 1
- Phase 1/2, Open Label, Dose Escalation Study of NEOD001 in Subjects With Light Chain (AL) AmyloidosisCompletedNCT01707264Phase 1/2
- High Cut-off Hemodialysis in Patients With Advanced Cardiac AL Amyloidosis and End Stage Renal DiseaseWithdrawnNCT01531751Phase 2
- Epigallocatechingallate (EGCG) in Cardiac AL AmyloidosisTerminatedNCT01511263Phase 2
- Pomalidomide and Dexamethasone (PDex) in AL AmyloidosisCompletedNCT01510613Phase 2
- Radioimmunoimaging of AL AmyloidosisCompletedNCT01409148Phase 1
- A Trial for Systemic Light-chain (AL) AmyloidosisCompletedNCT01277016Phase 3
- Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell TransplantActive, not recruitingNCT01199562
- Lendexal in Patients With Primary Systemic Amyloidosis (AL) Newly DiagnosedCompletedNCT01194791Phase 2
- Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for CancerCompletedNCT01053494Not applicable
- 3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With CancerActive, not recruitingNCT00935090
- Studying Fentanyl in Patients With CancerTerminatedNCT00899951
- Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral TherapyCompletedNCT00890747Phase 1
- A Trial of Treatment With Lenalidomide-Melphalan-Dexamethasone in Patients With Primary (AL) AmyloidosisCompletedNCT00883623Phase 2
- Radioimmunoimaging of AL AmyloidosisCompletedNCT00807872Phase 1
- Cyclophosphamide, Lenalidomide and Dexamethasone (CLD) for Previously Treated Patients With AL AmyloidosisCompletedNCT00607581Phase 2
- Intensive Versus Conventional Treatment in Patients With Primary AmyloidosisCompletedNCT00344526Phase 3
- Phase II Trial of Enbrel in Patients With Primary Systemic AmyloidosisCompletedNCT00224393Phase 2
- Autologous Stem Cell Rescue for Primary AmyloidosisCompletedNCT00186407Phase 2
- Mixed Chimeric Transplantation for Primary AmyloidosisWithdrawnNCT00186095Not applicable
- Efficacy of CC-5013 (Revlimid or Lenalidomide) in Patients With Primary Systemic AmyloidosisCompletedNCT00166413Phase 2
- Melphalan, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed, Previously Untreated Primary Systemic AmyloidosisCompletedNCT00089167Phase 2
- Amifostine and Melphalan in Treating Patients With Primary Systemic Amyloidosis Who Are Undergoing Peripheral Stem Cell TransplantationTerminatedNCT00052884Phase 1
- Iododoxorubicin in Treating Patients With Primary Systemic AmyloidosisTerminatedNCT00030381Phase 1
- Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver DysfunctionCompletedNCT00025415Phase 1
- Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic MalignanciesCompletedNCT00014235Not applicable
- Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Patients Who Have Multiple Myeloma or Primary Systemic AmyloidosisCompletedNCT00007995Phase 2
- Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic CancerCompletedNCT00006251Phase 1/2
- 4'-Iodo-4'-Deoxydoxorubicin in Treating Patients With Primary Systemic AmyloidosisCompletedNCT00003853Phase 2
- Interleukin-12 Followed by Interferon Alfa in Treating Patients With Advanced CancerCompletedNCT00003451Phase 1
- High-Dose Melphalan Plus Peripheral Stem Cell Transplantation in Treating Patients With Primary Systemic AmyloidosisCompletedNCT00003353Phase 2
- S9628 Dexamethasone Plus Interferon Alfa in Treating Patients With Primary Systemic AmyloidosisCompletedNCT00002849Phase 2